Blumhouse Atomic: James Wan and Jason Blum Name Their Merged Horror Studio

James Wan and Jason Blum have named their merged horror production operation Blumhouse Atomic, unveiling the umbrella title for the companies they combined in 2024. The announcement confirms that Blumhouse and Atomic Monster will keep operating as distinct production labels, with each creative team developing and producing film and television projects under its own banner.

The numbers behind the merger explain why the pair formalized the name. Since Wan and Blum joined forces, the combined banners have generated more than $2.5 billion in worldwide box office against combined production budgets of less than $330 million. In 2026 alone, Blumhouse Atomic pulled in $1.3 billion, carried by two of the year's biggest horror hits: Curry Barker's "Obsession," with $520 million worldwide, and Kane Parsons' "Backrooms," at $400 million worldwide.

What does the new company actually change?

In practice, the name consolidates the business side while preserving the two labels' separate identities. Blum laid out the logic in the announcement: "When we merged our companies, we believed the whole would be greater than the sum of its parts and that is exactly what has happened. Blumhouse Atomic is a natural evolution of what we've built together. 'The Conjuring' franchise, 'Insidious,' 'Saw,' no filmmaker has created more horror franchises than James Wan, and together we've brought some of the genre's most recognizable properties under one roof."

He also flagged a franchise reversal: "Bringing 'Saw' back to James, with a new chapter on the way, is a perfect example of what we can do together. We have the output of a studio with the creative freedom and financial discipline of an independent company, and more opportunities than ever to take these stories beyond the theater and into television, games and live experiences."

That last point matters. The company is signaling expansion past theatrical releases (a first-look deal and development slate aimed at games and live experiences are part of the plan) while keeping the low-budget model (blockbuster horror produced from undersized production budgets) that made both labels profitable.

Betting on new filmmakers

Wan framed the merged company as a talent engine rather than a consolidation play. "The future of horror comes from new voices, and Blumhouse Atomic gives us more ways to find them and support them for the long haul," he said. "I got my start with a small film and people willing to take a chance on it, so creating those opportunities for others is personal to me. Working with filmmakers like Kane Parsons, Curry Barker, Josh Giuliano and Dylan Clark is a big part of that. We want to give them the freedom to make something distinctive and build relationships that last beyond one film."

The structure backs that rhetoric with concrete moves made this year:

• Sam Zimmerman joined as senior vice president of development and acquisitions, tasked with building a slate of genre features with budgets under $5 million.
• The company signed a first-look deal with Divide/Conquer to develop high-concept projects at an economical rate.

The 2027 slate

Blumhouse Atomic's 2027 film lineup is heavy on franchise IP and new titles alike: "River," "The Revenge of La Llorona," "The Exorcist: Martyrs," "Anything But Ghosts," "Paranormal Activity," "Molepeople," "Blair Witch," "Sleepover" and "Seasons."

With the "Saw" franchise back under Wan's involvement and a nine-film slate ahead, Blumhouse Atomic enters 2027 positioned as the genre's dominant supplier — running at studio scale while spending like an independent.